Commentary
Video
Author(s):
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.
Adding an HPK1 Inhibitor to Immune Checkpoint Inhibition May Be Effective in Solid Tumors
Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases
How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors
FDA Approves Companion Diagnostic for Tepotinib in mNSCLC Harboring MET Exon 14 Skipping Alterations
Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma
Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma
IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL